Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.64 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.52 |
| ▸ | GSTK1 | Q9Y2Q3 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4962691 | 1.00 | FFAR4 (0.64) | FFAR4FFAR1LMNATSHRNFKB1 | |
| SCHEMBL3901066 | 1.00 | FFAR4 (0.64) | FFAR4FFAR1LMNATSHRNFKB1 | |
| SCHEMBL17129695 | 1.00 | FFAR4 (0.64) | FFAR4FFAR1LMNATSHRNFKB1 | |
| SCHEMBL3654757 | 1.00 | FFAR4 (0.64) | FFAR4FFAR1LMNATSHRNFKB1 | |
| SCHEMBL196231 | 1.00 | FFAR4 (0.64) | FFAR4FFAR1LMNATSHRNFKB1 | |
| SCHEMBL165539 | 1.00 | FFAR4 (0.64) | FFAR4FFAR1LMNATSHRNFKB1 | |
| SCHEMBL167866 | 1.00 | FFAR4 (0.64) | FFAR4FFAR1LMNATSHRNFKB1 | |
| SCHEMBL3933542 | 1.00 | FFAR4 (0.64) | FFAR4FFAR1LMNATSHRNFKB1 | |
| SCHEMBL196051 | 1.00 | FFAR4 (0.64) | FFAR4FFAR1LMNATSHRNFKB1 | |
| SCHEMBL195599 | 1.00 | FFAR4 (0.64) | FFAR4FFAR1LMNATSHRNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 567 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3766528-B1 | DRUG-COATED BALLOON CATHETERS FOR BODY LUMENS | UROTRONIC INC (US) | 2024-06-12 | — | — | EP | claimed |
| EP-3075401-B1 | PRESERVATION FOR COSMETIC, TOILETRY AND PHARMACEUTICAL COMPOSITIONS | INOLEX INVESTMENT CORP (US) | 2024-04-03 | — | — | EP | claimed |
| US-20240057589-A1 | EFFERVESCENT SOLID DOSAGE FORM COMPOSITIONS CONTAINING ENVIRONMENTALLY SAFER ANTI-MICROBIAL COMPONENTS | CHEMLINK LABORATORIES, LLC | 2024-02-22 | — | — | US | claimed |
| EP-4057996-B1 | AMORPHOUS PHARMACEUTICAL COMPOSITIONS OF ABIRATERONE ACETATE | SUVEN LIFE SCIENCES LTD (IN) | 2023-07-12 | — | — | EP | claimed |
| EP-3981385-B1 | EMOLLIENT AND CLEANSING AGENT | OLEON N V (BE) | 2023-06-21 | — | — | EP | claimed |
| US-20220387451-A1 | AMORPHOUS PHARMACEUTICAL COMPOSITIONS OF ABIRATERONE ACETATE | SUVEN LIFE SCIENCES LIMITED (IN) | 2022-12-08 | — | — | US | claimed |
| WO-2022146771-A1 | EFFERVESCENT SOLID DOSAGE FORM COMPOSITIONS CONTAINING ENVIRONMENTALLY SAFER ANTI-MICROBIAL COMPONENTS | CHEMLINK LABORATORIES, LLC (US) | 2022-07-07 | — | — | WO | claimed |
| WO-2021094992-A1 | AMORPHOUS PHARMACEUTICAL COMPOSITIONS OF ABIRATERONE ACETATE | SUVEN LIFE SCIENCES LIMITED (IN) | 2021-05-20 | — | — | WO | claimed |
| WO-2021058158-A1 | PRODUCT FOR DYEING KERATINOUS MATERIAL, CONTAINING AMINOSILICONE, A CHROMOPHORIC COMPOUND AND ETHOXYLATED FATTY ACID ESTER | HENKEL AG & CO. KGAA (DE) | 2021-04-01 | — | — | WO | claimed |
| EP-3547992-B1 | MIXTURES COMPRISING A PHENYL ALKANOL AND A LINEAR ALCOHOL WITH 8 TO 12 CARBON ATOMS | SYMRISE AG (DE) | 2020-12-30 | — | — | EP | claimed |
| EP-1148863-B1 | DETERGENT COSMETIC COMPOSITIONS AND USE | OREAL (FR) | 2002-06-26 | — | — | EP | claimed |
| WO-2001055128-A1 | FORMULATION FOR PROTECTION AGAINST OXIDATIVE STRESS CONTAINING BENZOFURANONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2001-08-02 | — | — | WO | claimed |
| EP-0754028-B1 | NOVEL DEODORISING AND ANTI-MICROBIAL COMPOSITIONS FOR USE IN COSMETIC OR TOPICAL PREPARATIONS | BEIERSDORF AG (DE) | 2000-09-06 | — | — | EP | claimed |
| US-6019988-A | COMPOSITIONS ARE PHYSICALLY SEPARATED UNTIL APPLICATION TO A BODY OR SKIN SURFACE AND ARE TOPICALLY APPLIED, EITHER AT THE SAME TIME, OR SEQUENTIALLY WITHIN A SHORT TIME OF EACH OTHER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-02-01 | — | — | US | claimed |
| EP-0540969-B1 | Derivatives of structurally modified VIP and pharmaceutical compositions containing them | YEDA RES & DEV (IL) | 1998-12-23 | — | — | EP | claimed |
| EP-0673648-B1 | Compositions comprising amphotoic salts of alpha-hydroxy acids and glycerol monocaprylate | BRISTOL MYERS SQUIBB CO (US) | 1998-11-25 | — | — | EP | claimed |
| EP-0613694-B1 | Ophthalmic lens with anti-toxin agent | JOHNSON & JOHNSON VISION PROD (US) | 1998-09-16 | — | — | EP | claimed |
| EP-0857488-A2 | Methods and compositions for enhancing skin permeation of drugs using permeation enhancers | Bristol-Myers Squibb Company (US) | 1998-08-12 | — | — | EP | claimed |
| EP-0368339-B1 | PHARMACEUTICAL PREPARATION FOR PERCUTANEOUS ADMINISTRATION CONTAINING BUNAZOSIN OR ITS SALT | Eisai Co., Ltd. (JP) | 1993-06-23 | — | — | EP | claimed |
| EP-0287036-B1 | NEW PHARMACEUTICAL COMPOSITIONS COMPRISING ESTERS OR AMIDES AS ACTIVE INGREDIENTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 1991-04-10 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387451-A1 | AMORPHOUS PHARMACEUTICAL COMPOSITIONS OF ABIRATERONE ACETATE | AR, KLK3, CYP19A1 | FFAR4 395/4885FFAR1 407/4885LMNA 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.